WallStreetZen

NYSE: NVO
Novo Nordisk A S Stock Forecast, Predictions & Price Target

Analyst price target for NVO

Based on 2 analysts offering 12 month price targets for Novo Nordisk A S.
Min Forecast
$72.70+0.25%
Avg Forecast
$73.85+1.83%
Max Forecast
$75.00+3.42%

Should I buy or sell NVO stock?

Hold
Strong Buy
1 analysts 20%
Buy
0 analysts 0%
Hold
3 analysts 60%
Sell
1 analysts 20%
Strong Sell
0 analysts 0%

Forecast return on equity

Is NVO forecast to generate an efficient return?
Company
99.17%
Industry
5.54%
Market
62.3%
NVO's Return on Equity is forecast to be high in 4 years (99.17%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NVO forecast to generate an efficient return on assets?
Company
42.22%
Industry
27.63%
Market
19.84%
NVO is forecast to generate higher Return on Assets (42.22%) than the US Biotechnology industry average (27.63%)
Forecast

NVO earnings per share forecast

What is NVO's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$3.02+5.38%
Avg 2 year Forecast
$3.30+15.05%
Avg 3 year Forecast
$3.66+27.79%
NVO's earnings are forecast to grow at a rate of 8.26% per year, which is not exceptional
Forecast

NVO revenue forecast

What is NVO's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$20.1B+2.9%
Avg 2 year Forecast
$22.1B+13.23%
Avg 3 year Forecast
$24.2B+23.95%
NVO's revenue is forecast to grow at a rate of 7.39% per year, which is not exceptional
Forecast

NVO earnings growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
8.26%
Industry
9.08%
Market
20.63%
NVO's earnings are forecast to grow slower (8.26% per year) than the US Biotechnology industry average (9.08%)
Forecast
NVO's earnings are forecast to grow slower (8.26% per year) than the US market average (20.63%)
Forecast
NVO's earnings are forecast to grow faster (8.26% per year) than the risk-free savings rate (1.1%)
Forecast

NVO revenue growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
7.39%
Industry
65.67%
Market
14.47%
NVO's revenues are forecast to grow slower (7.39% per year) than the US Biotechnology industry average (65.67%)
Forecast
NVO's revenues are forecast to grow slower (7.39% per year) than the US market average (14.47%)
Forecast

Novo Nordisk A S Stock Forecast FAQ

Is Novo Nordisk A S Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: NVO) stock is to Hold NVO stock.

Out of 5 analysts, 1 (20%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 3 (60%) are recommending NVO as a Hold, 1 (20%) are recommending NVO as a Sell, and 0 (0%) are recommending NVO as a Strong Sell.

What is NVO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year NVO price target, the average NVO price target is $73.85, with the highest NVO stock price forecast at $75.00 and the lowest NVO stock price forecast at $72.70.

On average, Wall Street analysts predict that Novo Nordisk A S's share price could reach $73.85 by Jan 18, 2022. The average Novo Nordisk A S stock price prediction forecasts a potential upside of 1.83% from the current NVO share price of $72.52.

What is NVO's earnings growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual earnings growth rate of 8.26% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.63%.

Novo Nordisk A S's earnings in 2020 is $6,720,937,500.On average, 5 Wall Street analysts forecast NVO's earnings for 2021 to be $7,116,142,200, with the lowest NVO earnings forecast at $6,602,120,000, and the highest NVO earnings forecast at $7,851,807,000. On average, 4 Wall Street analysts forecast NVO's earnings for 2022 to be $7,769,280,500, with the lowest NVO earnings forecast at $7,309,490,000, and the highest NVO earnings forecast at $8,323,387,000.

In 2023, NVO is forecast to generate $8,629,914,000 in earnings, with the lowest earnings forecast at $8,087,597,000 and the highest earnings forecast at $9,172,231,000.

What is NVO's revenue growth forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 7.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.

Novo Nordisk A S's revenue in 2020 is $19,544,531,250.On average, 3 Wall Street analysts forecast NVO's revenue for 2021 to be $47,418,703,571,400, with the lowest NVO revenue forecast at $45,663,209,295,000, and the highest NVO revenue forecast at $50,669,078,153,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2022 to be $52,178,895,754,700, with the lowest NVO revenue forecast at $50,061,635,955,000, and the highest NVO revenue forecast at $56,273,664,979,000.

In 2023, NVO is forecast to generate $57,121,129,607,500 in revenue, with the lowest revenue forecast at $53,533,054,230,000 and the highest revenue forecast at $60,709,204,985,000.

What is NVO's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: NVO) Novo Nordisk A S's current Earnings Per Share (EPS) is $2.86. On average, analysts forecast that NVO's EPS will be $3.02 for 2021, with the lowest EPS forecast at $2.80, and the highest EPS forecast at $3.33. On average, analysts forecast that NVO's EPS will be $3.30 for 2022, with the lowest EPS forecast at $3.10, and the highest EPS forecast at $3.53. In 2023, NVO's EPS is forecast to hit $3.66 (min: $3.43, max: $3.89).

What is NVO's forecast return on equity (ROE) for 2021-2024?

(NYSE: NVO) forecast ROE is 99.17%, which is considered strong.

What is NVO's forecast return on assets (ROA) for 2021-2024?

(NYSE: NVO) forecast ROA is 42.22%, which is higher than the forecast US Biotechnology industry average of 27.63%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics